瑞舒伐他汀与阿托伐他汀两种药物治疗冠心病随机对照研究

Atorvastatin Versus Rosuvastatin for Coronary Heart Disease:a Randomized Controlled Trial

目的对两种不同他汀类药物治疗冠心病的疗效进行研究。方法随机选取2013年6月—2014年12月该院收治的100例冠心病患者作为研究对象,将其随机分为对照组和观察组,每组50例患者。对照组患者使用阿托伐他汀进行治疗,观察组患者使用瑞舒伐他汀进行治疗。对两组患者的疗效进行观察对比。结果在经过2个月的治疗后,观察组患者的总胆固醇含量明显低于对照组(t=3.7963,P=0.0003),低密度脂蛋白胆固醇含量明显低于对照组(t=3.5082,P=0.0007)。对照组患者血脂浓度达标率为64%,观察组患者血脂浓度达标率为82%,观察组患者的血脂浓度达标率明显高于对照组(X^2=4.0196,P=0.043)。结论与阿托伐他汀相比,瑞舒伐他汀的疗效更为显著,能够起到有效降低血脂的作用,同时还不会使患者的肝功能受到损伤,值得在临床上进一步推广。

Objective To study the effect of two different statins in the treatment of coronary heart disease. Methods A total of 100 patients with coronary heart disease （CHD） admitted to our hospital from June 2013 and December 2014 were selected as research object and randomly divided into control group and observation group, 50 cases in each group. Patients in the control group were treated with atorvastatin, while those in the observation group were treated with rosuvastatin. The curative effects of the two groups were compared. Results After treatment for 2 months, total cholesterol levels of the observation group was significantly lower than that of the control group （t=3.7963, P=0.0003）,and low density lipoprotein cholesterol of the observation group was significantly lower than that of the control group （t=3.5082,P=0.0007）. Compliance rate of blood lipid concentration of the observation group , 82%,was obviously higher than that of control group, 64%（χ^2=4.0196, P=0.043）. Conclusion Compared with atorvastatin, the cu-rative effect of rosuvastatin is more significant, and it can reduce blood lipid and protect liver function effectively, so it is worthy of further promotion in clinic.